[New advances and future prospect in antifungal therapy for invasive pulmonary aspergillosis].

This article a comprehensive review of recent advances in the treatment of invasive pulmonary aspergillosis (IPA), with a focus on emerging antifungal drugs, innovations in drug-delivery approaches, and evolving therapeutic strategies. New antifungal agents, such as isavuconazole, new formulations of posaconazole, liposomal amphotericin B, rezafungin, and eravacycline, exhibit distinct pharmacokinetic, pharmacodynamic, and safety profiles. Nanoparticle delivery systems and inhaled formulations have increased drug concentrations at the airway site while reducing systemic adverse effects. Future research will focus on new drug development targeting fungal protein targets, multi-target approaches, and immunomodulatory therapies.